FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

$\bigcirc$	ΛD	AΡ	DD	$\sim$	/ A I
( )1	ЛΚ	AΡ	РΚ	( ) \	/AI

OMB Number:	3235-0287
Estimated average burden	
	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Ins	e conditions of Rule struction 10.							
1. Name and Address AULT MILT	. 0	on *	2. Issuer Name and Ticker or Trading Symbol Alzamend Neuro, Inc. [ ALZN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last)	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/23/2025	Officer (give title Other (specify below) below)				
11411 SOUTHERN HIGHLANDS PARKWAY SUITE 190			4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check App X Form filed by One Reporting Person					
(Street)				Form filed by More than One Reporting Person				
LAS VEGAS	NV	89141						
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	12/23/2025		S <sup>(1)</sup>		1,851	D	\$2.0665	0	D	
Common Stock								8,260	I	By Ault Lending, LLC <sup>(2)</sup>
Common Stock								11,068	I	By Ault Life Sciences, Inc. <sup>(3)</sup>
Common Stock								61	I	By Ault Life Sciences Fund, LLC <sup>(4)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivat Securit Acquire or Disp	Derivative Expiration (Month/ Securities (Month/ Dr Disposed of D) (Instr. 3, 4			Securities Underlying		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

#### Explanation of Responses:

- 1. Such shares were sold at the direction of the reporting person, for purposes of realizing tax losses.
- 2. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- 3. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
- 4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

### Remarks:

By: /s/ Milton C. Ault, III, Chief Executive Officer of Ault &

12/30/2025

Company, Inc.

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.